Prognostic value of galec- tin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323 8. 122. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108:385 90. 123. Tang WH, Wu Y, Grodin JL, et al. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. J Am Coll Cardiol HF. 2016;4:68 77. 124. Januzzi JL, Mebazaa A, Di SS. ST2 and prognosis in acutely decompen- sated heart failure: the International ST2 Consensus Panel. Am J Cardiol. 2015;115:26B 31B. 125. Mebazaa A, Di SS, Maisel AS, et al. ST2 and multimarker testing in acute decompensated heart failure. Am J Cardiol. 2015;115:38B 43B. 126. Fermann GJ, Lindsell CJ, Storrow AB, et al. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers. 2012;17:706 13. 127. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168:2186 94. 128. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429 35. 129. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293 302. 130. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, Yancy et al lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 